G1 Therapeutics, Inc. (GTHX)

Market Cap	128.09M
Revenue (ttm)	84.04M
Net Income (ttm)	-30.59M
Shares Out	52.28M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	607,920
Open	2.480
Previous Close	2.470
Day's Range	2.335 - 2.510
52-Week Range	1.080 - 6.140
Beta	1.71
Analysts	Strong Buy
Price Target	8.00 (+226.53%)
Earnings Date	Jul 31, 2024

About GTHX

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2017
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: GTHX

Financial Performance

In 2023, GTHX's revenue was $82.51 million, an increase of 60.84% compared to the previous year's $51.30 million. Losses were -$47.97 million, -67.49% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for GTHX stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 226.53% from the latest price.

Price Target

$8.0

(226.53% upside)

Analyst Consensus: Strong Buy